Federico Pulido

Summary

Publications

  1. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
  2. ncbi request reprint Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine, Madrid, Spain
    J Acquir Immune Defic Syndr 35:343-50. 2004
  3. ncbi request reprint Treatment of advanced HIV infection
    Federico Pulido
    HIV CareUnit, Hospital Universitario 12 de Octubre, Ctra Andalucia km 5 4, 28041 Madrid, Spain
    J Antimicrob Chemother 51:225-7. 2003
  4. ncbi request reprint [Once-a-day highly active antiretroviral therapy. Present or future?]
    Federico Pulido
    Unidad VIH, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Espana
    Med Clin (Barc) 121:304-9. 2003
  5. ncbi request reprint Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009
  6. ncbi request reprint High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)
    Jose R Arribas
    Internal Medicine Service, La Paz Hospital, Autonoma University School of Medicine, Madrid, Spain
    AIDS 16:1554-6. 2002
  7. doi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
    Jose R Arribas
    Servicio de Medicina Interna, Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    J Acquir Immune Defic Syndr 51:147-52. 2009
  8. doi request reprint Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 48:455-9. 2008
  9. pmc Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 8:20. 2008
  10. ncbi request reprint Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists
    Eva Poveda
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Rev 14:208-17. 2012

Detail Information

Publications51

  1. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  2. ncbi request reprint Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine, Madrid, Spain
    J Acquir Immune Defic Syndr 35:343-50. 2004
    ..To compare the clinical, immunologic, and virologic outcomes of efavirenz (EFV)-based versus protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) in severely immunosuppressed HIV-1-infected patients...
  3. ncbi request reprint Treatment of advanced HIV infection
    Federico Pulido
    HIV CareUnit, Hospital Universitario 12 de Octubre, Ctra Andalucia km 5 4, 28041 Madrid, Spain
    J Antimicrob Chemother 51:225-7. 2003
  4. ncbi request reprint [Once-a-day highly active antiretroviral therapy. Present or future?]
    Federico Pulido
    Unidad VIH, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Espana
    Med Clin (Barc) 121:304-9. 2003
  5. ncbi request reprint Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009
    ..Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined...
  6. ncbi request reprint High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)
    Jose R Arribas
    Internal Medicine Service, La Paz Hospital, Autonoma University School of Medicine, Madrid, Spain
    AIDS 16:1554-6. 2002
    ..Efavirenz-based HAART was found to be effective in profoundly immunosuppressed HIV-1-infected patients...
  7. doi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
    Jose R Arribas
    Servicio de Medicina Interna, Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    J Acquir Immune Defic Syndr 51:147-52. 2009
    ..However, it is still uncertain if this experimental strategy can maintain suppression in the long term...
  8. doi request reprint Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 48:455-9. 2008
    ..The aims of the present study were to determine if metabolic abnormalities and cytokine derangements are modified in HIV-1-infected patients after 12 months on treatment interruption (TI)...
  9. pmc Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 8:20. 2008
    ..The aim was to identify predictive markers of CD4+ cell count declines to < 350/microL in CD4-guided antiretroviral treatment interruptions...
  10. ncbi request reprint Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists
    Eva Poveda
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Rev 14:208-17. 2012
    ..This review updates clinical and methodological recommendations for genotypic determination of HIV tropism to guide therapeutic decisions using CCR5 antagonists, considering the most recently reported data...
  11. doi request reprint Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad HIV, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    J Antimicrob Chemother 61:1359-61. 2008
    ..Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented...
  12. doi request reprint Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 16:59-65. 2011
    ..When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes...
  13. ncbi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
    Federico Pulido
    Unidad HIV and Laboratorio de Microbiología Molecular, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    AIDS 22:F1-9. 2008
    ..Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful...
  14. doi request reprint Lack of the detection of XMRV or polytropic MLV-related sequences in blood cells from HIV-1-infected patients in Spain
    Joanna Luczkowiak
    Laboratory of Molecular Microbiology, Instituto de Investigación i 12, Hospital Universitario 12 de Octubre, Madrid, Spain
    J Acquir Immune Defic Syndr 59:101-4. 2012
    ..Because the existence of XMRV raises many questions, we decided to study its presence in a group of patients infected with HIV-1 with a high proportion of intravenous drug use and coinfection by hepatitis C virus...
  15. ncbi request reprint [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:13-8. 2008
    ....
  16. doi request reprint [Clinico-epidemiological characteristics of HIV-positive immigrants: study of 371 cases]
    Jara Llenas-García
    Unidad VIH, Hospital Universitario 12 de Octubre, Madrid, Espana
    Enferm Infecc Microbiol Clin 30:441-51. 2012
    ..Our objective is to describe the clinico-epidemiological characteristics of HIV-positive immigrants seen in a specialist unit in Madrid...
  17. pmc Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
    Asuncion Diaz
    Unidad de Epidemiología del VIH SIDA, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    BMC Infect Dis 10:267. 2010
    ..The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion...
  18. pmc Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy
    José F Pascual-Pareja
    Microbiology Department, Hospital Universitario 12 de Octubre, Avenida de Cordoba sn, 28041 Madrid, Spain
    J Clin Microbiol 48:1911-2. 2010
    ..Upon multivariate analysis, factors associated with detection of VLs between 20 and 49 copies/ml by the Cobas TaqMan HIV-1 v2.0 assay in an HIV clinic were the basal VL and time on antiretroviral therapy...
  19. ncbi request reprint Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality
    Paz Sobrino-Vegas
    Red de Investigación en SIDA, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    Curr HIV Res 7:224-30. 2009
    ..Although we did not find differences in virological and immunological responses to HAART, we did observe higher mortality in people with DHD. Increased efforts to early diagnose HIV infection are urgently needed...
  20. doi request reprint [HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008]
    Ana María Caro-Murillo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, CIBERESP, Madrid, Espana
    Med Clin (Barc) 134:521-7. 2010
    ..To describe the characteristics of HIV infected adults according to their age at recruitment in CoRIS...
  21. ncbi request reprint Impact of hepatitis C co-infection on response to antiretroviral treatment
    Federico Pulido
    Hospital 12 de Octubre, Madrid, Spain
    AIDS Rev 14:124-31. 2012
    ..The low percentage of HIV/HCV co-infected patients in this analysis, compared with published cohort studies, suggests that HCV co-infected patients are underrepresented in HIV clinical trials...
  22. doi request reprint The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
    Jose R Arribas
    Hospital La Paz, Madrid, Spain
    AIDS 24:223-30. 2010
    ..In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides...
  23. ncbi request reprint NNRTI hepatotoxicity: efavirenz versus nevirapine
    Federico Pulido
    Unidad VIH, Hospital 12 de Octubre, S 28041 Madrid, Spain
    J HIV Ther 7:S3-16. 2002
  24. doi request reprint [Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]
    Asuncion Diaz
    Unidad de Epidemiología del VIH SIDA, Instituto de Salud Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 28:215-21. 2010
    ..In this report we analyze the incidence and variables associated with non-prescription of TST in a cohort of HIV-infected people...
  25. doi request reprint Should we look for strongyloides stercoralis in foreign-born HIV-infected persons?
    Jara Llenas-García
    HIV Unit, Instituto de Investigación Hospital 12 de Octubre I 12, Universidad Complutense de Madrid, Madrid, Spain
    J Immigr Minor Health 15:796-802. 2013
    ..5 % seroreversion). Screening of HIV-positive immigrants may be desirable, at least in those with higher risk of hyperinfection syndrome. Serologic testing seems a useful tool in both diagnosis and follow-up of these patients. ..
  26. ncbi request reprint [Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients]
    Ismael Escobar
    Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:490-4. 2006
    ..The pharmacoeconomic analysis was performed from the perspective of the Spanish public health system...
  27. doi request reprint Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS)
    Gonzalo Yebra
    FiBIO IRYCIS Hospital Ramón y Cajal and CIBER ESP, Madrid, Spain
    Antiviral Res 89:19-25. 2011
    ..We evaluated the reliability of subtyping tools vs. phylogeny in a panel of HIV-1 pol sequences from the cohort of naïve patients of the HIV/AIDS Spanish Research Network (CoRIS)...
  28. doi request reprint Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006
    Santiago Pérez Cachafeiro
    National Epidemiology Centre, Instituto de Salud Carlos III, Madrid, Spain
    Clin Infect Dis 48:1467-70. 2009
    ..8% in 1997 to 19.8% in 2006. This steady decrease in the prevalence of coinfection among Spanish patients was caused by a change in transmission routes of HIV infection...
  29. ncbi request reprint Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists
    Eva Poveda
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Rev 12:135-48. 2010
    ..This review summarizes clinical and methodological recommendations for the genotypic determination of HIV tropism to guide therapeutic decisions with CCR5 antagonists in HIV therapeutics...
  30. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
    ..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients...
  31. ncbi request reprint Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors
    Maria Luisa Montes
    Internal Medicine Service, La Paz Hospital, Autonoma University School of Medicine, Madrid, Spain
    J Antimicrob Chemother 55:800-4. 2005
    ..The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients...
  32. ncbi request reprint [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]
    Ana María Caro-Murillo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 25:23-31. 2007
    ..To describe the methodology and baseline results of the Spanish cohort of naïve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS)...
  33. doi request reprint Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient
    Lorena Martinez-Prats
    Hospital Universitario 12 de Octubre, Madrid, Spain
    AIDS Res Hum Retroviruses 27:41-5. 2011
    ..Clonal analysis of different plasma and cellular samples within this period did not reveal any reversion to the wild-type genotype...
  34. doi request reprint Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
    Jara Llenas-García
    HIV Unit, Instituto de Investigación Hospital 12 de Octubre I 12, Universidad Complutense, Madrid, Spain
    AIDS Care 25:980-9. 2013
    ..In conclusion, more than a third of HIV-infected immigrant patients are susceptible to at least one easily preventable infectious disease. Especial attention should be given to immigrant women of childbearing age...
  35. ncbi request reprint [Interpreting methodological and statistical considerations in studies of rescue therapy]
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:47-52. 2008
    ..The present review discusses changes in the design of these studies, the main methodological issues to be taken into account and the recommendations on this subject...
  36. doi request reprint Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus
    Juan Berenguer
    Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Hepatol 58:1104-12. 2013
    ..Here, we assess the impact of end-of-treatment response with subsequent relapse (REL) on LR events (LR death, liver decompensation, hepatocellular carcinoma, or liver transplantation), and liver stiffness (LS) by transient elastography...
  37. ncbi request reprint Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy
    Juan Berenguer
    Services of Infectious Diseases, Hospital Gregorio Maranon, 28007, Madrid, Spain
    Clin Infect Dis 34:394-7. 2002
    ..No reactivation or progression of retinitis was observed in 35 patients with persistent response to HAART, findings that support the discontinuation of secondary prophylaxis against CMV retinitis in such patients...
  38. ncbi request reprint [Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection]
    Rosa Polo
    Consejera Técnica, Plan Nacional sobre el Sida, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:96-117. 2006
    ..To provide an update of the metabolic and morphologic alterations in patients infected with HIV with an in-depth analysis of their clinical management and treatment...
  39. ncbi request reprint Factors affecting patient adherence to highly active antiretroviral therapy
    Ismael Escobar
    Department of Pharmacy, University Hospital Doce de Octubre, Madrid, Spain
    Ann Pharmacother 37:775-81. 2003
    ..To determine the clinical and demographic variables related to adherence to highly active antiretroviral therapy (HAART) in patients treated in our hospital and identify the characteristics of nonadherent patients...
  40. pmc Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy
    Ignacio Pérez-Valero
    HIV Unit Internal Medicine Service, Hospital Universitario La Paz IdiPAZ, Madrid, Madrid, Spain
    PLoS ONE 8:e69493. 2013
    ....
  41. ncbi request reprint Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997
    Francisco Javier San-Andrés
    Medicina Familiar y Comunitaria, Centro de Salud Potes, Guadalajara 19003, Spain
    Clin Infect Dis 36:1177-85. 2003
    ..A reduction in the incidence of AIDS-related ODs was observed, mainly in patients who underwent prophylaxis. Adherence to antiretroviral treatment and PCP prophylaxis was associated with a reduction in the risk of disease...
  42. ncbi request reprint The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone
    John E McKinnon
    University of Pittsburgh, Pensylvania, USA
    AIDS 20:2331-5. 2006
    ..To determine whether the level of persistent HIV-1 viremia is affected by simplifying standard antiretroviral therapy to lopinavir/ritonavir (LPV/r) alone...
  43. ncbi request reprint Underpowered clinical trials of antiretroviral treatment
    Jose R Arribas
    JAMA 288:2120; author reply 2120-1. 2002
  44. doi request reprint Noninferiority and lopinavir/ritonavir monotherapy trials
    Federico Pulido
    AIDS 22:1696-7. 2008
  45. ncbi request reprint Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy
    Jose R Arribas
    J Acquir Immune Defic Syndr 46:118; author reply 118-9. 2007
  46. ncbi request reprint Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy
    Asuncion Costa
    AIDS 16:1983-4. 2002
  47. ncbi request reprint Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment
    Joanna Z Peng
    Abbott Laboratories, Clinical Pharmacology and Pharmacometrics Department R4PK, Building AP13A 3, 100 Abbott Park Road, Abbott Park, IL 60064 6104, USA
    J Clin Pharmacol 46:265-74. 2006
    ..While lopinavir/ritonavir dose reduction is not recommended in subjects with mild or moderate hepatic impairment, caution should be exercised in this population...
  48. ncbi request reprint [Spanish recommendations for proper use of enfuvirtide]
    Esteban Ribera
    Hospital Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:131-42. 2007
    ....
  49. ncbi request reprint Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)
    Jose R Arribas
    Hospital La Paz, Consulta de Medicina Interna II, Paseo de la Castellana, 28046 Madrid, Spain
    J Acquir Immune Defic Syndr 40:280-7. 2005
    ..This study evaluated maintenance with lopinavir/ritonavir monotherapy vs. continuing lopinavir/ritonavir and 2 nucleosides in HIV-infected patients with suppressed HIV replication...
  50. ncbi request reprint Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients
    Bonaventura Clotet
    Germans Trias i Pujol Universitary Hospital, Badalona, Spain
    HIV Clin Trials 5:33-9. 2004
    ....
  51. ncbi request reprint [Antiretroviral treatment in patient with advanced immunosuppression]
    Jose R Arribas
    Med Clin (Barc) 126:157-8; author reply 158-9. 2006